MaxCyte, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MXCT research report →
Range $4 – $4
Price Chart
About the company
MaxCyte, Inc. , a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.
- CEO
- Maher Masoud
- IPO
- 2021
- Employees
- 91
- HQ
- Rockville, MD, US
Get TickerSpark's AI analysis on MXCT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $141.45M
- P/E
- -5.18
- PEG
- -0.09
- P/S
- 4.12
- P/B
- 0.94
- EV/EBITDA
- -6.15
- Div Yield
- 0.00%
- Gross Margin
- 78.02%
- Op Margin
- -87.65%
- Net Margin
- -81.40%
- ROE
- -17.24%
- ROIC
- -17.92%
Latest fiscal year · YoY change
- Revenue
- $33.03M-14.5%
- Gross Profit
- $26.80M-15.0%
- Op Income
- $-45,285,000
- Net Income
- $-44,630,000-8.7%
- EPS
- $-0.42-7.7%
- OCF Growth
- -24.6%
- FCF Growth
- -23.6%
- 52W High
- $1.80
- 52W Low
- $0.64
- 50D MA
- $1.25
- 200D MA
- $1.08
- Beta
- 1.48
- RSI (14)
- 55
- Avg Volume
- 1.04M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
MaxCyte reported strong Q3 growth, raised full-year guidance, and announced a transformational acquisition of Akron that management says will nearly double revenue and speed its path to profitability.· November 10, 2026
- Q3 total revenue was $10.2 million, up 49% year over year, with core revenue of $8.2 million up 27% and SPL program revenue of $2 million.
- Gross margin was 83% versus 77% a year ago; management said full-year gross margins should remain in the high 70s.
- Full-year 2026 guidance was raised to at least $34.5 million of total revenue, including about $28 million of core revenue and at least $6.5 million from SPL milestones and royalties.
- Management announced a definitive agreement to acquire Akron for $151.8 million, saying the combined company should generate more than $60 million of 2026 revenue pro forma.
- The deal is expected to add $3 million to $4 million of annual cost synergies and reduce annual cash burn to less than $10 million in 2027 on a combined basis.
Third-quarter 2026 total revenue was $10.2 million, up 49% from $6.8 million a year ago. Core revenue was $8.2 million versus $6.4 million, up 27%; instrument revenue was $2.8 million versus $1.4 million, license revenue was $2.0 million versus $1.8 million, and processing assembly revenue was $3.1 million versus $2.6 million. SPL program-related revenue was $2.0 million versus $0.4 million last year, including a $1 million milestone and about $1 million of royalty revenue. Gross margin was 83% versus 77% last year, and non-GAAP adjusted gross margin was 80% versus 81%. Total operating expenses were $14.5 million versus $19.4 million, and year-to-date operating expenses were about $44 million versus about $62 million, with year-to-date net loss of about $18 million versus about $35 million. Guidance for full-year 2026 now calls for at least $34.5 million of total revenue, including about $28 million of core revenue and at least $6.5 million of SPL milestones and royalties, and at least $133 million in pro forma year-end cash, cash equivalents and investments. Management also said MaxCyte standalone 2026 annual cash burn is expected to be about $17 million, while combined-company annual cash burn is expected to be less than $10 million in 2027.
Maher Masoud framed the Akron acquisition as a major strategic step that broadens MaxCyte from a mainly electroporation-focused platform into a broader cell therapy manufacturing partner spanning both viral and nonviral workflows. He emphasized that Akron brings durable, recurring commercial revenue, a larger addressable market, and a much lower customer concentration profile, while also extending MaxCyte’s reach earlier and later in the development cycle. His tone was highly confident and optimistic, repeatedly describing the deal as a best-in-class fit and a meaningful accelerant toward profitability and a stronger 2027 base.
Parmeet Ahuja focused on the financial profile of both businesses and the transaction structure. He said Akron is expected to generate about $28 million of 2026 revenue, $7 million to $8 million of EBITDA, and has a gross margin in the mid-60% range, with operating expenses of about $10 million to $11 million annually excluding noncash items. For MaxCyte standalone, he detailed Q3 results, noted operating expenses fell to $14.5 million from $19.4 million a year ago, and said the company ended Q3 with $132.7 million in cash and investments and no debt. He also said the company expects $3 million to $4 million of deal-related cost synergies, at least $133 million in pro forma year-end cash, and combined annual cash burn below $10 million in 2027, while funding the acquisition primarily with cash on hand plus a MidCap facility.
Analysts pressed management on how Akron would be integrated commercially, how much cross-selling opportunity exists, and whether the business mix and gross margins can improve further after the deal. Management said Akron’s lean commercial team will be paired with MaxCyte’s broader sales force in the U.S., Europe, and Asia-Pacific, and that the bigger opportunity is not just the current 10% customer overlap but the remaining 90% of the combined base. Questions on the Q3 instrument strength and PA trends were answered by clarifying that the instrument strength was mainly a timing shift from a large pharma customer, while PA demand was said to have stabilized and should continue growing. Analysts also asked about forecasting around late-stage approvals and about ExiCAR assay services, with management saying it has better visibility into ordering patterns now and that assay services are still lumpy quarter to quarter.
The call showed MaxCyte exiting the year with improving core growth, stronger SPL royalties, and a raised full-year revenue target. Management also sees Akron as a profitable, cash-generating asset that broadens the platform, expands the TAM, and increases recurring revenue visibility while reducing customer concentration. They were explicit that the combined company should have a stronger path to profitability and more stable revenue entering 2027.
Q4 may be softer after the timing-related Q3 instrument benefit, and management noted some revenue lines like assay services remain lumpy. The acquisition adds integration execution risk, new debt, and dependence on realizing $3 million to $4 million of expected synergies. Management also pointed to seasonality in CASGEVY and the inherent uncertainty of late-stage and commercial program timing, even though they said forecasting has improved.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 91.9%
- Shares Outstanding
- 103.25M
- Float Shares
- 94.86M
of shares held by institutions
125 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Capricorn Fund Managers Ltd | 8.20M | 0 |
| Vanguard Group Inc | 5.54M | ▼ 48.83K |
| Vitruvian Partners Llp | 5.04M | 0 |
| Liontrust Investment Partners Llp | 4.84M | ▲ 4.84M |
| Vanguard Capital Management LLC | 4.01M | ▼ 22.32K |
| Morgan Stanley | 3.98M | ▲ 287.13K |
| Blackrock, Inc. | 3.03M | ▼ 34.45K |
| Bnp Paribas Asset Management Holding S.A. | 2.77M | 0 |
| Cadian Capital Management, LP | 2.62M | ▲ 423.52K |
| Two Sigma Investments, LP | 2.41M | ▲ 946.92K |
| Mudita Advisors Llp | 2.26M | ▼ 1.11M |
| Renaissance Technologies LLC | 2.04M | ▲ 124.50K |
Held by 33 ETFs
Biggest fund positions in MXCT by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 17, 26 | Masoud Maher | buy | 100,000 |
| Jun 17, 26 | Johnston John Joseph | other | 30,421 |
| Jun 17, 26 | Johnston John Joseph | other | 49,579 |
| Jun 17, 26 | Hemrajani Rekha | other | 30,421 |
| Jun 17, 26 | Hemrajani Rekha | other | 49,579 |
| Jun 17, 26 | Erck Stanley C | other | 30,421 |
| Jun 17, 26 | Erck Stanley C | other | 49,579 |
| Jun 17, 26 | DOUGLAS RICHARD | other | 30,421 |
| Jun 17, 26 | DOUGLAS RICHARD | other | 49,579 |
| Jun 17, 26 | Collins Cynthia | other | 30,421 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our MXCT coverage
Recent articles, reports, and earnings notes.
No research on MXCT yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MXCT report →MaxCyte, Inc. (MXCT) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 11
MaxCyte Q3 Earnings Call Highlights
marketbeat.com · Nov 10
MaxCyte Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Total Revenue Guidance
globenewswire.com · Nov 10
MaxCyte to Acquire Akron Bio, Expanding its Offerings Across Cell Therapy Manufacturing and Expecting to Nearly Double Revenue Base
globenewswire.com · Nov 10
MaxCyte to Participate in Three Upcoming Investor Conferences
globenewswire.com · Oct 28
MaxCyte Reports Preliminary Third Quarter 2026 Revenue and Raises Full Year 2026 Revenue Guidance
globenewswire.com · Oct 14
MaxCyte Appoints Sidharth Kapileshwar as Chief Corporate Development Officer
globenewswire.com · Sep 23
MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Sep 11
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.